Video Experimental Relacionado
Updated: Sep 10, 2025
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.6K
Una serie de casos de penfigoide bullosa asociada con vildagliptina - Efecto secundario raro
Mohit Kumar Shahi1, J V Ashwin1, Astha Singh2
1Department of GMH, King George Medical University, Lucknow, Uttar Pradesh, India.
Indian journal of pharmacology
|August 22, 2025
Resumen
La vildagliptina, un agente hipoglucémico oral común, puede desencadenar el pemfigoide bulloso, una afección cutánea que produce ampollas. Esta serie de casos destaca a tres pacientes que desarrollaron este trastorno autoinmune después de comenzar el tratamiento con vildagliptina para la diabetes tipo 2.
Área de la Ciencia:
- Endocrinología
- Dermatología
- Inmunología
Sus antecedentes:
- La vildagliptina es un agente hipoglucémico oral (OHA) de la clase de inhibidores de la dipeptidilpeptidasa-4 (DPP-4).
- Los inhibidores de la DPP-4 se utilizan ampliamente para el tratamiento de la diabetes mellitus tipo 2 (DM2).
- El penfigoide bulloso (BP) es una enfermedad autoinmune con ampollas que afecta a la piel y las membranas mucosas.
Videos de Conceptos Relacionados
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416